Bank of America
IOVA icon

Bank of America’s Iovance Biotherapeutics IOVA Stock Holding History

Bank of America’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,700
Closed -$467K – 8312
2022
Q3 		$467K Buy
+48,700
New +$562K ﹤0.01% 5457

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Bank of America's IOVA Position: Q1 2026 in Review

Bank of America reduced its Iovance Biotherapeutics (IOVA) stake by 41% in Q1 2026, selling an estimated $18.5M and leaving 8,490,119 shares worth $29.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Bank of America first reported a position in IOVA in Q2 2015 and has held it in 43 quarters since. The position peaked at $149M in Q4 2020. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Bank of America held 8,490,119 shares of Iovance Biotherapeutics worth $29.8M as of Q1 2026.
  • Bank of America sold 5,787,694 Iovance Biotherapeutics shares in Q1 2026, an estimated $18.5M.
  • Iovance Biotherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2043 holding.
  • Bank of America first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 43 quarters since.
  • Bank of America's Iovance Biotherapeutics position peaked at $149M in Q4 2020.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.